Home>>Signaling Pathways>> Cardiovascular>> Vasodilation>>CB-096

CB-096

Catalog No.GC52006

An inhibitor of RAN translation

Products are for research use only. Not for human use. We do not sell to patients.

CB-096 Chemical Structure

Cas No.: 108883-90-5

Size Price Stock Qty
10 mg
$303.00
In stock
50 mg
$1,062.00
In stock
100 mg
$1,817.00
In stock
250 mg
$3,787.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

CB-096 is an inhibitor of repeat-associated non-ATG (RAN) translation.1 It selectively binds to the hexanucleotide GGGGCC repeat expansion (r(G4C2)exp) hairpin r(G4C2)8 (EC50 = 19 µM) over the anti-sense hairpin r(G2C4)8 and base-paired construct r(GGCC)10. CB-096 (25 µM) inhibits RAN translation and the formation of nuclear stress granules in HEK293T cells expressing r(G4C2)66 in an in vitro model of C9orf72 amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) (c9ALS/FTD). It also induces relaxation of rat thoracic aortic rings pre-contracted with norepinephrine (EC50 = 1.81 µM) and decreases systolic arterial pressure in conscious spontaneously hypertensive rats when administered at a dose of 100 mg/kg.2

1.Ursu, A., Wang, K.W., Bush, J.A., et al.Structural features of small molecules targeting the RNA repeat expansion that causes genetically defined ALS/FTDACS Chem. Biol.15(12)3112-3123(2020) 2.Navarrete-VÁzquez, G., Hidalgo-Figueroa, S., Torres-Piedra, M., et al.Synthesis, vasorelaxant activity and antihypertensive effect of benzo[d]imidazole derivativesBioorg. Med. Chem.18(11)3985-3991(2010)

Reviews

Review for CB-096

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for CB-096

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.